IMBiotechnologies Ltd, a medical device company located in Edmonton, Alberta, announced its latest approval from Health Canada. This approval has expanded the use of the organization’s product, the Ekobi Embolization Microspheres. This latest approval allows the microspheres to be used for treating uterine fibroids.
IMB’s Ekobi utilizes a minimally invasive technique called embolotherapy, which blocks certain blood vessel with microspheres. The target tissue is then starved of oxygen and nutrients. The benefit of the Ekobi microspheres is that they biodegrade and are completely removed from the patient’s anatomy. Also, these microspheres are the only embolic agent detectable by ultrasound.
In a statement from CEO of IMB, Michael Stewart, he said the following,
“Uterine fibroids can have a major impact on a woman’s physical and social activities. We are pleased to offer physicians a biodegradable and non-surgical treatment option for symptomatic uterine fibroids.”
When looking into the gynecological market in women’s health, iData discovered a new trend. For many years, the uterine fibroid embolization market has been trending towards microspheres, at the expense of PVA particles. As microspheres have a much higher ASP, costing nearly twice as much as PVA particles. However, this method has not been practiced for a significant amount of time however, so there is no long-term data available on the effect of this treatment on pregnancy. As such, the pool of potential patients is limited women who do not intend to become pregnant. It will be interesting to see how the Ekobi from IMB drives the market-long term as more data becomes available.
For Further Information
To get in an in-depth market overview of 20 countries, with insight through primary research and procedural volumes, please read iData Research’s’ 3,650 page Gynecological Devices Market Analysis, Size and Trends Report.
